Brief: Sagimet Biosciences Reports Second Quarter 2023 Financial Results And Provides Corporate Updates
21/08/2023 21:13
Aug 21 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATES
* SAGIMET BIOSCIENCES INC- IMPLEMENTED LEADERSHIP CHANGES
WITH
TONY RIMAC ASSUMING POSITION OF CHIEF FINANCIAL OFFICER
* SAGIMET BIOSCIENCES INC: ON TRACK TO REPORT TOPLINE WEEK
52
LIVER BIOPSY RESULTS FROM PHASE 2B FASCINATE-2 TRIAL IN Q1 OF
2024
* SAGIMET BIOSCIENCES INC- CASH AND CASH EQUIVALENTS FOR Q2
ENDED
JUNE 30, 2023 WERE $18.5 MILLION AS OF JUNE 30, 2023
* SAGIMET BIOSCIENCES INC- QTRLY LOSS PER SHARE $35.80
Source text for Eikon: ID:nGNX7Q615T
Further company coverage: SGMT.O
(Reporting by Zaheer Kachwala)
((Zaheer.Kachwala@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage